Attaining and wisely spending online marketing budgets is essential for companies operating in the digital space. How companies secure their digital marketing budgets and choose to spend them varies across surveyed pharmaceutical and device organziations. Some companies have a formal budgeting process in place for attaining digital marketing funding. Others receive budgets on an ad-hoc basis. Regardless of how these organizations receive their funding, allocating their available resources often marks the difference between companies’ abilities to develop successful, meaningful digital campaigns versus ones that fall flat after only a few months. Continue reading “Making the Most of Digital Marketing Budgets to Produce Valuable Initiatives” »
Telemedicine is back — and with good reason. As it stands, patients can find visiting a doctor, especially for non-serious concerns, to be frustrating and time-consuming. Already, patients spend inordinate amounts of time traveling to and from physician offices just to spend more time in the doctors’ waiting room. This patient-centric technology is poised to help healthcare consumers cut the time expenditure required to address minor health concerns. With cold and flu season a not-so-distant memory, most end-users would agree that telemedicine is a useful tool for patients who are not in dire medical straits, but could still benefit from some key health advice. Continue reading “[Telemedicine’s] Back. Tell A Friend.” »
Mobile health (mHealth) has been touted for its ability to increase mHealth adherence, facilitate remote data analysis and — if all goes according to plan — revolutionize healthcare as we know it. The US FDA has only recently released a guidance discussing how it will regulate mHealth initiatives while the EU already has a web of legal framework outlining mHealth regulations. Cutting Edge Information’s recent study on mHealth finds that Top 20 companies rank EMA and in-country regulations each as a 3.9 out of 5 in terms of difficulty to work with.
But don’t worry app developers of Europe – the EU is on it! Continue reading “EU and mHealth: Increasing Patient Adherence and Healthcare Efficiency While Protecting Consumers” »
The pharmaceutical commercial environment is currently in flux as both life science organizations and healthcare professionals adjust to recent changes. Pharmaceutical and medical device organizations are still feeling the impact of two major patent cliffs as well as diminished sales force sizes. Physicians, on the other hand, are responding to evolving regulations, including the 2013 implementation of the Physician Payment Sunshine Act. In many cases, medical institutions and doctors are limiting their interactions with pharmaceutical firms. As prescribers’ doors close, life sciences organizations must evolve their pharmaceutical sales strategies to meet these physician access challenges. Continue reading “Target Acquired: Employing Closed-Loop Marketing to Maximize Physician Segmentation Processes and Refine Pharmaceutical Sales Strategies” »
Ad boards and their related costs are a growing area of interest in the life sciences industry. A sampling of companies surveyed by Cutting Edge Information recently reported their spending for an average pharmaceutical ad board conducted in the US. Among surveyed companies, the average multinational clinical ad board convened in the US costs $129,000. A national clinical ad board in the US costs these same companies an average of $78,000 while a local ad board costs an average of $36,000. Continue reading “Surveyed Companies Reveal Pharmaceutical Ad Board Costs” »
Working with payers and hospitals in order to maintain profitability is a key role for managed markets groups and the account managers responsible for these contacts. Payers are becoming increasingly interested in data that demonstrate the efficacy and value of products to their patients. And in this case, pharmaceutical reimbursement strategies can be informed by something as simple as the favorite snack of a little bear from the Hundred Acre Wood. Continue reading “Pharmaceutical Reimbursement Strategy: What We Can All Learn From Winnie the Pooh” »
A theme that emerged at World Congress’ Second Annual Summit on The Evolving Role of Medical Affairs and Thought Leader Engagement in an Era of Transparency, held in Philadelphia from May 20 to 21, is that medical affairs teams face universal challenges — regardless of whether they’re housed within large Top 50 drug makers, small specialty biotechs or medical device companies. The greatest challenge to these teams is not necessarily the effects of new transparency regulations, but rather, the same internal obstacle that these teams have faced for decades: how to prove their value to senior leadership.
The presentations delivered by some of the industry’s most experienced medical affairs leaders highlighted several key themes that underscore common challenges Continue reading “The Value of Medical Affairs Lies in Its Ties to Patient Care” »
When it comes to managing and nurturing thought leader relationships and specifically the process of identifying key opinion leaders, companies have several options. Many choose to outsource the identification process and contact KOLs once they’ve been identified by the third-party vendor. For larger and mid-sized companies that are looking to expand into new therapeutic areas or geographic regions, vendors provide an extremely valuable and effective service. Continue reading “KOL Management for Small Pharma Leans Heavily on Existing Networks Within Companies” »